Literature DB >> 19188354

Generation of antibody responses to pneumococcal capsular polysaccharides is independent of CD1 expression in mice.

Leen Moens1, Axel Jeurissen, Stefan Nierkens, Louis Boon, Luc Van Kaer, Ahmad Kasran, Greet Wuyts, Jan L Ceuppens, Xavier Bossuyt.   

Abstract

Streptococcus pneumoniae is a bacterial microorganism that frequently causes serious infection, particularly in children and the elderly. Protection against infection with S. pneumoniae is based mainly on the generation of antibodies to the pneumococcal capsular polysaccharides (caps-PS), but the mechanisms responsible for the generation of anticapsular antibodies remain incompletely understood. The aim of the present study was to evaluate the role of CD1-restricted T cells in the antibody response to caps-PS. When immunized with Pneumo23, wild-type mice and CD1 knockout mice on BALB/c and C57BL/6 backgrounds generated immunoglobulin M (IgM) and IgG antibody responses to soluble caps-PS that were comparable. Similar results were obtained after immunization with heat-inactivated S. pneumoniae. The IgM and IgG antibody response of wild-type mice to Pneumo23 was not affected by an antagonizing monoclonal anti-CD1 antibody treatment. In summary, our data provide evidence that the antibody response to caps-PS is generated independently of CD1 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19188354      PMCID: PMC2681747          DOI: 10.1128/IAI.01091-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  T cell regulation of the antibody response to bacterial polysaccharide antigens: an examination of some general characteristics and their implications.

Authors:  P J Baker
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

2.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 3.  CD1-restricted T cells and resistance to polysaccharide-encapsulated bacteria.

Authors:  R M Fairhurst; C X Wang; P A Sieling; R L Modlin; J Braun
Journal:  Immunol Today       Date:  1998-06

4.  In vivo polysaccharide-specific IgG isotype responses to intact Streptococcus pneumoniae are T cell dependent and require CD40- and B7-ligand interactions.

Authors:  Z Q Wu; Q Vos; Y Shen; A Lees; S R Wilson; D E Briles; W C Gause; J J Mond; C M Snapper
Journal:  J Immunol       Date:  1999-07-15       Impact factor: 5.422

5.  Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules.

Authors:  C V Harding; R W Roof; P M Allen; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

6.  CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells.

Authors:  J H Roark; S H Park; J Jayawardena; U Kavita; M Shannon; A Bendelac
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

Review 7.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

Review 8.  Natural killer T cells as targets for immunotherapy of autoimmune diseases.

Authors:  Luc Van Kaer
Journal:  Immunol Cell Biol       Date:  2004-06       Impact factor: 5.126

9.  Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.

Authors:  A W Griffioen; G T Rijkers; P Janssens-Korpela; B J Zegers
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

10.  Polysaccharide processing and presentation by the MHCII pathway.

Authors:  Brian A Cobb; Qun Wang; Arthur O Tzianabos; Dennis L Kasper
Journal:  Cell       Date:  2004-05-28       Impact factor: 41.582

View more
  1 in total

1.  Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine.

Authors:  Guillaume Goyette-Desjardins; Cynthia Calzas; Tze Chieh Shiao; Axel Neubauer; Jennifer Kempker; René Roy; Marcelo Gottschalk; Mariela Segura
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.